Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Antibody- and gene-directed enzyme prodrug therapy are two-step targeting strategies designed to improve the selectivity of antitumour agents. The approaches are based on the activation of specially designed prodrugs by antibody-enzyme conjugates targeted to tumour-associated antigens (ADEPT) or by enzymes expressed by exogenous genes in tumour cells (GDEPT). Herein the design, synthesis, physico-chemical and biological properties, kinetics and clinical trials of the prodrugs and the enzymes carboxypeptidase G2 and nitroreductase are reviewed for ADEPT and GDEPT.
Niculescu-Duvaz
I
I
CRC Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK.
Friedlos
F
F
Niculescu-Duvaz
D
D
Davies
L
L
Springer
C J
CJ
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D015195:Drug Design; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D011355:Prodrugs
D000912:Antibodies, Neoplasm; D011355:Prodrugs